Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Novartis Gene Therapies Plans Denton, Texas, Operations

03/04/2026
Novartis Gene Therapies, a biotechnology business within Novartis, plans to establish operations in Denton, Texas. The $280 million project is expected to create 150 jobs.

The investment will include the construction of a 46,000-square-foot radioligand therapy manufacturing facility that will serve patients in the Southern U.S and add network capacity as RLT expands into earlier treatment lines and additional tumor types. Production is scheduled to begin in 2028.

“RLT has the potential to revolutionize cancer care,” said Vas Narasimhan, CEO of Novartis. “The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”

To support the project Denton City Council members unanimously approved $3.2 million in tax incentives, including; real property tax abatement at 50% for 10 years for new improvements ($2.3 million); a sales tax rebate at 50% on construction materials ($200,000); a Job-based grants ($300,000); and a Remediation grant ($395,000).

“Texas is a leading biotech hub and home to groundbreaking advancements in medicine,” noted Governor Greg Abbott. “This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”

Novartis Gene Therapies specializing in developing and commercializing advanced gene-therapy treatments for rare and life-threatening genetic diseases, particularly neurological disorders. The company develops therapies that address the underlying genetic cause of disease by delivering functional genes directly to patients’ cells.

Exclusive Research